Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.